Increased reengagement of out-of-care HIV patients using Lost & Found, a clinic-based intervention.

Authors:
Linthwaite B; Kronfli N; Marbaniang I; Ruppenthal L; Lessard D and 4 more

Journal:
AIDS

Publication Year: 2022

DOI:
10.1097/QAD.0000000000003147

PMCID:
PMC8876436

PMID:
34897240

View on PubMed View on PMC View Publisher
Journal Information

Full Title: AIDS

Abbreviation: AIDS

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Acquired Immunodeficiency Syndrome

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Criteria for classification, nomenclature, and reference sequence selection for HIV sub-subtypes of…
Wang D; Feng Y; Ruan Y and 6 more (2024) - Transparency Score: 3/6
Trends in HIV preexposure prophylaxis utilization and spending among individuals with commercial in…
Dickson S; James K. (2024) - Transparency Score: 2/6
A genetic variation in fucosyltransferase 8 accelerates HIV-1 disease progression indicating a role…
van Pul L; Maurer I; Boeser-Nunnink BDM and 3 more (2023) - Transparency Score: 3/6
Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in C…
Costiniuk CT; Singer J; Lee T and 28 more (2023) - Transparency Score: 4/6
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, f…
Wilck M; Barnabas S; Chokephaibulkit K and 15 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest J.C. has received consulting fees from ViiV Healthcare, Merck, and Gilead; research funding from ViiV Healthcare, Merck and Gilead; and payment for lectures from Gilead. N.K. has received consulting fees from ViiV Healthcare, Merck and Gilead; research funding from ViiV Healthcare and Gilead; and payment for lectures from Gilead. B. Lebouché has received consulting fees from ViiV Healthcare Merck and Gilead; research funding from Merck, Gilead, ViiV Healthcare; and payment for lectures from Merck, Gilead and ViiV Healthcare. All other authors declare that they have no competing interests."

Evidence found in paper:

"Funding: This study is funded by ViiV Healthcare."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025